IDEAYA Biosciences Q3 EPS $(0.46) Beats $(0.49) Estimate, Sales $8.04M Beat $7.32M Estimate
Portfolio Pulse from Benzinga Newsdesk
IDEAYA Biosciences reported Q3 losses of $(0.46) per share, beating the analyst consensus estimate of $(0.49) by 6.12 percent. This is a 1250 percent decrease over earnings of $0.04 per share from the same period last year. The company also reported quarterly sales of $8.04 million, beating the analyst consensus estimate of $7.32 million by 9.81 percent, but a 72.94 percent decrease over sales of $29.70 million the same period last year.
November 07, 2023 | 11:15 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
IDEAYA Biosciences reported better than expected Q3 results but with significant decreases compared to last year.
While IDEAYA Biosciences beat Q3 estimates, the significant year-over-year decreases in both earnings and sales could potentially offset any positive sentiment from beating estimates. The impact on the stock price is uncertain in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100